In the fourth quarter of 2011, the profit of the Israeli Teva, a global producer of generic drugs, rose by 23% to 1.4 billion dollars. The increase in profits was driven by contributions from US-based Cephalon, a biotech company specializing in drugs for the central nervous system, pain and oncology, acquired in 2011.
(Il Sole 24 Ore Pag.30 – 16/02/2012)
